Entdecken

Infectious risk in Crohn's disease under immunomodulators
Dieser Artikel steht derzeit nicht zur Verfügung!
60,90 € *

inkl. MwSt. zzgl. Versandkosten

Derzeit nicht lieferbar.

  • Our Knowledge Publishing
  • Yosra Zaimi
  • KNV96155606
  • 9786205262665
Immunomodulators have revolutionized the management of chronic inflammatory bowel disease.... mehr
Produktinformationen "Infectious risk in Crohn's disease under immunomodulators"
Immunomodulators have revolutionized the management of chronic inflammatory bowel disease. Nevertheless, they are associated with an increased risk of opportunistic infections (OIs). The aim of our study was to investigate OIs in Crohn's disease on immunomodulators and to identify associated factors. 77 were included with a M/F sex ratio of 0.75 and a mean age of 45.6 years. A pre-immunomodulator workup was performed in all patients. Antituberculosis chemoprophylaxis was prescribed in 18% of patients. Viral serologies B and C were positive in 8 and 4% of cases. OI occurred in 42 patients with a mean time between treatment with immunomodulators and the occurrence of infection of 3.3 years. OIs were ubiquitous. The infection was bacterial in 71% of cases with a predominance of E.Coli, parasitic in 12% of cases, fungal in 12% of cases and viral in 5% of patients. In a multivariate study, the combination of azathioprine and corticosteroids was the independent predictive factor for the occurrence of OI (p<0.001).
Weiterführende Links zu "Infectious risk in Crohn's disease under immunomodulators"
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Infectious risk in Crohn's disease under immunomodulators"
Bewertung schreiben
Bewertungen werden nach Überprüfung freigeschaltet.
Bitte geben Sie die Zeichenfolge in das nachfolgende Textfeld ein.

Die mit einem * markierten Felder sind Pflichtfelder.

Zuletzt angesehen